The life sciences IPO market has faced significant headwinds in recent years, but signs of a potential reopening in the capital markets are emerging. As investor sentiment shifts and regulatory landscapes evolve, biotech and healthcare companies must be strategic in their approach to going public. The New England Healthcare Network (NEHEN) will bring together industry experts to discuss the latest trends, key considerations for IPO readiness, and what it takes to successfully access public markets in today’s environment.
Foley Hoag Partner and Capital Markets Co-Chair, Stacie Aarestad will serve as a panelist. She will be joined by Eric Dimise, Sector Lead, Healthcare & Life Sciences, NYSE; Griffin Ehlen, Director, Investment Banking, Craig-Hallum Capital Group; Paul Gudonis, CEO, Myomo; and Rebecca Stevenson, Head of Healthcare Investment Banking, HSBC. The discussion will be moderated by Dan Giampietro, Senior Advisor of Life Science at The Baldwin Group.
For more information, visit the
NEHEN website.
